Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
This month, Novo sued telehealth provider Hims & Hers for alleged patent infringement and issued a 2026 outlook that disappointed investors, all while its stock swung wildly. In this article Maziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one – but recent weeks have delivered more drama than most companies might expect over a decade. The Danish drugmaker kicked off the year with the explosive launch of the first-ever GLP-1 pill for obesity. Its recent challenges have centered around protecting its market share in the blockbuster weight loss drug market, all while its stock price swings wildly. This week, Novo sued upstart telehealth provider Hims & Hers for alleged patent infringement and received its own warning from the U.S. Fo
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk plans Wegovy vials amid obesity-drug competition [Yahoo! Finance]Yahoo! Finance
- West Pharma forecasts 2026 profit above estimates on strong demand for drug components [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at Jefferies Financial Group Inc. from an "underperform" rating to a "hold" rating.MarketBeat
- Novo CEO blasts ‘mass compounding' of GLP-1 drugs as safety battle escalates [FOX Business Network]FOX Business Network
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/11/26 - Form 6-K
- 2/10/26 - Form 6-K
- 2/9/26 - Form 6-K
- NVO's page on the SEC website